9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

TMIGD2 Human

Transmembrane And Immunoglobulin Domain Containing 2 Human Recombinant RCP2392

Product Overview

Name	TMIGD2 Human

Description

Transmembrane And Immunoglobulin Domain Containing 2 Human Recombinant

Accession (Primary)	Q96BF3

Synonyms

IGPR-1, IGPR1,TMIGD2, Transmembrane and immunoglobulin domain-containing protein 2 isoform1, CD28 homolog, CD28H, Immunoglobulin and proline-rich receptor 1.

Source

HEK293 Cells.

Physical Appearance

Sterile Filtered colorless solution.

Formulation

The TMIGD2 solution (1mg/ml) contains 10% Glycerol and Phosphate-Buffered Saline (pH 7.4).

Stability

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

Purity

Greater than 95.0% as determined by SDS-PAGE.

Amino acid sequence

LSVQQGPNLL QVRQGSQATL VCQVDQATAW ERLRVKWTKD GAILCQPYIT NGSLSLGVCG PQGRLSWQAP SHLTLQLDPV SLNHSGAYVC WAAVEIPELE EAEGNITRLF VDPDDPTQNR NRIASFPG LE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPGK .

Biological Activity

The ED50 range is ≤ 200 ng/ml and is measured by its binding ability in a functional ELISA with Human HHLA2.

Background

TMIGD2 in Autoimmune Disorders: Conversely, dysregulation of TMIGD2 may contribute to autoimmune disorders, where the immune system mistakenly targets the body's own tissues. Investigations into TMIGD2 Human Recombinant may shed light on its role in immune tolerance and the prevention of excessive immune reactions. Deciphering the nuances of TMIGD2's functions provides potential insights for therapeutic interventions in autoimmune conditions. Challenges and Future Directions: While the potential of TMIGD2 Human Recombinant in immune modulation is promising, challenges persist. Fine-tuning its applications, understanding its interactions with various immune cell types, and deciphering the context-dependent nature of its functions are critical considerations for translational success. Additionally, exploring the potential dual role of TMIGD2 in cancer immunity and autoimmune disorders poses a challenge in the pursuit of targeted therapeutic strategies. TMIGD2 Human Recombinant emerges as a promising protagonist in the narrative of immune modulation, offering a controlled platform for scientific exploration. Its structural insights, cellular functions, and implications in immune regulation position it as a key player in the evolving landscape of immunotherapy and immune-related disorders. As researchers continue to unravel the molecular intricacies of TMIGD2, they not only deepen our understanding of immune responses but also pave the way for transformative advancements in cancer immunotherapy and autoimmune disease therapeutics, shaping the future of precision medicine and immunomodulatory interventions.

Precautions

TMIGD2 Human is for research use only and not for use in diagnostic or therapeutic procedures.

Target Information: (Q96BF3)

Background

TMIGD2 in Autoimmune Disorders: Conversely, dysregulation of TMIGD2 may contribute to autoimmune disorders, where the immune system mistakenly targets the body's own tissues. Investigations into TMIGD2 Human Recombinant may shed light on its role in immune tolerance and the prevention of excessive immune reactions. Deciphering the nuances of TMIGD2's functions provides potential insights for therapeutic interventions in autoimmune conditions. Challenges and Future Directions: While the potential of TMIGD2 Human Recombinant in immune modulation is promising, challenges persist. Fine-tuning its applications, understanding its interactions with various immune cell types, and deciphering the context-dependent nature of its functions are critical considerations for translational success. Additionally, exploring the potential dual role of TMIGD2 in cancer immunity and autoimmune disorders poses a challenge in the pursuit of targeted therapeutic strategies. TMIGD2 Human Recombinant emerges as a promising protagonist in the narrative of immune modulation, offering a controlled platform for scientific

9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

exploration. Its structural insights, cellular functions, and implications in immune regulation position it as a key player in the evolving landscape of immunotherapy and immune-related disorders. As researchers continue to unravel the molecular intricacies of TMIGD2, they not only deepen our understanding of immune responses but also pave the way for transformative advancements in cancer immunotherapy and autoimmune disease therapeutics, shaping the future of precision medicine and immunomodulatory interventions.